Anyone Can Now Take This Breast Cancer Gene Test, But It Probably Won’t Tell You Much
Breast and ovarian cancers are scary, anxiety-provoking diseases, and with good reason. Although breast cancer isn’t the cancer that kills the most women ( lung cancer holds that distinction ), it is the most commonly diagnosed cancer in women. And ovarian cancer is difficult to find in its early stages . But anyone willing to spit in a tube and pay $199 will soon be able to find out if they have a particular genetic predisposition to either of these cancers. This month, the FDA granted the genetics company 23andMe permission to offer direct-to-consumer testing for three of the more than 1,000 known variants of the genes BRCA1 and BRCA2 1 that have been found to confer an increased risk 2 of breast and ovarian cancer. (The tests were previously only available through a doctor.) But not everyone is celebrating. Because the gene variants found by the test are extremely rare, most people who take the test won’t come awa...